TY  - CHAP
M1  - Book, Section
TI  - Renal Cell Carcinoma
A1  - Motzer, Robert J.
A2  - Jameson, J. Larry
A2  - Fauci, Anthony S.
A2  - Kasper, Dennis L.
A2  - Hauser, Stephen L.
A2  - Longo, Dan L.
A2  - Loscalzo, Joseph
PY  - 2018
T2  - Harrison's Principles of Internal Medicine, 20e
AB  - Renal  cell  carcinomas  account  for  90–95%  of  malignant  neoplasms  arising  from  the  kidney.  Notable  features  include  diagnosis  without  symptoms,  resistance  to  cytotoxic  agents,  infrequent  responses  to  biologic  response  modifiers  such  as  interleukin  (IL)-2,  robust  activity  of  antiangiogenesis-targeted  agents,  and  a  variable  clinical  course  for  patients  with  metastatic  disease,  including  anecdotal  reports  of  spontaneous  regression.  The  remaining  5–10%  of  malignant  neoplasms  arising  from  the  kidney  are  transitional  cell  carcinomas  (urothelial  carcinomas)  originating  in  the  lining  of  the  renal  pelvis.  See  Chap.  82  for  transitional  cell  carcinomas.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/20
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1156514368
ER  -